With the deal, Eli Lilly gains a drug called lebrikizumab, designed to treat eczema. If successful in phase 3 clinical trials, the drug could compete against Dupixent, a commercial blockbuster for Sanofi and Regeneron Pharmaceuticals, according to STAT. Midstage trials showed that Eli Lilly’s new drug could be more effective than Dupixent and would require less frequent dosing.
Eli Lilly will also get Qbrexza, a drug developed by Dermira to treat excessive underarm sweating.
The all-cash deal is expected to close by the end of the first quarter of 2020.
Read the full article here.
More articles on pharmacy:
California governor to announce state-run generic drug company
Celgene backs out of $55M drug monopoly settlement
CVS, Walgreens sue Ohio physicians, claim they share blame for opioid crisis
